A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Inclusion Criteria: * Informed Consent form signed by the patient or patient's legal representative; also, if the patient is under the age of majority but capable of providing assent, signed assent from the patient * Diagnosis of junctional or dystrophic EB. * Patients who present with Hallopeau-Siemens subtype may be enrolled. * At least one active, unroofed EB erosion on the limb or on the trunk. * Lesion size 5 to 50 cm2, inclusive. * Stable lesion present for 14-60 days before enrollment. * More that one member in a family can be enrolled as long as that member is treated to a different cohort with an assurance that the study medication will not be shared. * No clinically significant abnormalities (Grade 2 or higher on the National Cancer Institute \[NCI\] toxicity scale) on Screening laboratory tests, except for the following specific laboratory threshold result: albumin must be 2 g/dL or higher; hemoglobin must be 8 g/dL or higher. Exclusion Criteria: * Clinical evidence of local infection of the index (targeted) lesion. * Use of any investigational drug within the 30 days before enrollment. * Use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment. * Use of systemic or topical steroidal therapy within the 30 days before enrollment.Inhaled steroids are allowed. * Use of systemic antibiotics within the 7 days before enrollment. * Current or former malignancy. * Arterial or venous disorder resulting in ulcerated wounds. * Diabetes mellitus. * Pregnancy or breastfeeding during the study. (A serum pregnancy test will be performed at Screening for female patients of childbearing potential.)